Resources Case Studies Coding & Billing Implementation Tools Package Inserts Product Information Videos, Webinars, & Podcasts Select ProductPlateletsAll ProductsIFCPlasmaPlateletsPRPCRSelect Resource TypeAll Resource TypesCase StudiesCoding & BillingImplementation ToolsPackage InsertsProduct InformationVideos, Webinars, & PodcastsUINTERCEPT Goes Beyond – Platelets and IFCINTERCEPT Blood System for PlateletsINTERCEPT Blood System Mechanism of ActionAssessing Platelet Availability – PR vs. LVDSUse of PR Platelets for Patient Safety and SustainabilityOptimizing Platelet Availability and Access to 100% PR InventoryUS Tertiary Care Hospital Gains Operational Efficiency and Fresher PlateletsVersiti PR Scale-UpImplementation of PR at Puerto Rico Blood Center During Zika OutbreakStanford Blood Center Implements 100% PRPlatelets and Plasma Outpatient Information GuideISBT Platelets CodesBest Practices Platelet Handling Guide – HospitalsPR Platelets Implementation GuideNurse Handout TemplateSample Labels SheetSample SBAR SheetSample Tie Tags SheetNurse Training ModuleImplementing INTERCEPT Platelets – E-learning TestPlatelets Small Volume (SV) – INT2130BPlatelets Large Volume (LV) – INT2230BPlatelets Dual Storage (DS) – INT2530BPlatelets Dual Storage (DS) Semi-Integrated Set – INT2540BPlatelets Small Volume (SV) Semi-Integrated Set – INT2140BPlatelets Large Volume (LV) Semi-Integrated Set – INT2240BINTERCEPT Integrated Sets Specifications InsertINTERCEPT Platelets Interview: Dr. Deva Sharma – Vanderbilt University Medical CenterINTERCEPT Platelets Interview: Dr. Shannon Walker – Vanderbilt University Medical CenterINTERCEPT Platelets Interview: Dr. Maria De Los Angeles Muñiz – Robert Wood Johnson University HospitalINTERCEPT Plasma Specifications InsertCMV Mitigation SheetPlatelets Safety and Efficacy Technical SheetINTERCEPT Semi-integrated Sets Specifications InsertPR – Proactive Strategy for Blood Safety in Pandemic PreparationMethodologies for Reducing the Risk of TA-GVHD from Platelet TransfusionsComparing Useable Shelf-life of PR Platelets vs LVDS Screened Platelets – OneBloodImpact of PR vs LVDS Testing on Platelet AvailabilityThe Effects of PAS and PR on Platelet Use – Roswell Park Cancer InstituteLogistical Management of Incorporating Pathogen Reduced Platelets into Inventory – Yale New-Haven HospitalSafety and Efficacy of Amotosalen-UVA PR Platelet Components Transfused to Mature and Premature Neonates – Cerus CorporationPhased Implementation of Pathogen-Reduced Platelets – UCSDPlatelets Economic Model – RutgersImpact of Amotosalen/UVA Process for PR in PLT Concentrates on Transfusion Efficiency in Cardiac Surgery – Saint-Etienne, France2022 AABB Abstract BookINTERCEPT Platelets Publications List2023 AABB Abstract BookSeptic Transfusion Reaction AwarenessLocal transmission of dengue virus – considerations for blood safety and the role of PRPathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT® Fibrinogen Complex or IFC) and INTERCEPT® treated Platelets: Expanding the Use of Pathogen Reduction for Improved Blood SafetyImplementing Pathogen Reduced Platelets: A TSO (Transfusion Safety Officer) Perspective (Allegheny Health Network)Evaluating Usable Shelf-Life of Pathogen Reduced and LVDS Tested Platelet ComponentsAssessing Platelet Availability from Blood Center and Hospital PerspectivesReview of Neonate to Pediatric Patient Outcomes Transfused with Amotosalen/UVA Treated PlateletsHemostatic Efficacy of Pathogen Reduced Platelets in Pediatric Cardiopulmonary BypassImpact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The PIPER StudyMerits and Pitfalls of Automated Bacterial Culture Methods in Improving Bacterial Safety of Platelet ConcentratesImpact of Anaerobic Culture of Platelets on Safety and OperationsImplementing Pathogen Reduced Platelets: A TSO (Transfusion Safety Officer) Perspective (Johns Hopkins All Children’s Hospital)Pathogen Reduced Platelet Implementation at Stanford HospitalThe Rationale for Pathogen Reduction: Blood Center and Transfusion Services PerspectivesPlatelet Pathogen Reduction Technology Implementation at Stanford Blood CenterPlatelet Component Bacterial Risk Control: An Evolution in ProgressPathogen Reduction of Platelets: Patient Safety and FDA Platelet Bacterial Guidance CompliancePathogen Reduction of Platelets: Guidance Compliance and ImplementationPreparing Our Blood Supply for the Next Pandemic with Dr. Susan StramerUpdating a Software Model to Estimate the Cost and Shelf Life Implications of New Platelet TechnologiesImplementing Pathogen Reduced (PR) INTERCEPT Platelets and Pediatric Considerations
INTERCEPT Platelets Interview: Dr. Maria De Los Angeles Muñiz – Robert Wood Johnson University Hospital
Logistical Management of Incorporating Pathogen Reduced Platelets into Inventory – Yale New-Haven Hospital
Safety and Efficacy of Amotosalen-UVA PR Platelet Components Transfused to Mature and Premature Neonates – Cerus Corporation
Impact of Amotosalen/UVA Process for PR in PLT Concentrates on Transfusion Efficiency in Cardiac Surgery – Saint-Etienne, France
Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT® Fibrinogen Complex or IFC) and INTERCEPT® treated Platelets: Expanding the Use of Pathogen Reduction for Improved Blood Safety
Implementing Pathogen Reduced Platelets: A TSO (Transfusion Safety Officer) Perspective (Allegheny Health Network)
Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The PIPER Study
Merits and Pitfalls of Automated Bacterial Culture Methods in Improving Bacterial Safety of Platelet Concentrates
Implementing Pathogen Reduced Platelets: A TSO (Transfusion Safety Officer) Perspective (Johns Hopkins All Children’s Hospital)
Updating a Software Model to Estimate the Cost and Shelf Life Implications of New Platelet Technologies